Literature DB >> 8897453

P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue.

H Wittenburg1, R Bültmann, B Pause, C Ganter, G Kurz, K Starke.   

Abstract

Effects of Evans blue and four derivatives as well as of trypan blue and four derivatives, mostly smaller fragments but two compounds with an additional ethylene bridge in the center of the molecule, were studied on contractions of the rat vas deferens elicited by alpha, beta-methylene ATP (alpha, beta-MeATP; mediated by P2X-purinoceptors), relaxations of the carbachol-precontracted guinea-pig taenia coli elicited by adenosine 5'-O-(2-thiodiphosphate) (ADP beta S; mediated by P2Y-purinoceptors), and the degradation of ATP by rat vas deferens tissue. All compounds shifted the concentration-response curve of alpha, beta-MeATP in the rat vas deferens to the right, and most compounds increased the maximum of the curve. Each member of the Evans blue series was similar in potency to the corresponding member of the trypan blue series. Where three concentrations were tested, the Arunlakshana-Schild regression was linear, and the slope did not differ from 1. The apparent Kd values were between 0.8 and 385 microM. In the guinea-pig taenia coli, only the members of the trypan blue group were relatively potent, shifting the concentration-response curve of ADP beta S to the right in a surmountable manner. In 2 of 3 cases where three concentrations were tested, the slope of the Arunlakshana-Schild regression was lower than 1. Apparent Kd values in the trypan blue group were between 5.2 and 324 microM. The removal of ATP from the medium by vas deferens tissue was decreased mainly by the members of the Evans blue group, with IC25% values between 13 and 158 (in 1 case > 1000) microM. The results indicate that the position of the sulphonate residues at the terminal naphthalene rings of these compounds hardly influences P2X purinoceptor affinity but greatly influences P2Y affinity and ecto-nucleotidase blockade. Among active compounds, apparent purinoceptor affinity and ecto-nucleotidase blockade increase with the size of the molecules up to Evans blue and trypan blue themselves; introduction of a central ethylene bridge does not result in a further gain in potency. NH01, the desmethyl derivative of Evans blue, seems to be interesting because it is the compound with the highest P2X- versus P2Y-selectivity presently available.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897453     DOI: 10.1007/bf00168441

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Authors:  R Bültmann; O Dudeck; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

2.  P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

Authors:  R Bültmann; B Pause; H Wittenburg; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

3.  P2-purinoceptor antagonists discriminate three contraction-mediating receptors for ATP in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

4.  Reactive red 2: a P2y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

5.  A study on P2X purinoceptors mediating the electrophysiological and contractile effects of purine nucleotides in rat vas deferens.

Authors:  B S Khakh; A Surprenant; P P Humphrey
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Two relaxation-mediating P2-purinoceptors in guinea-pig taenia caeci.

Authors:  O Dudeck; R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

8.  Blockade of P2X-purinoceptors by trypan blue in rat vas deferens.

Authors:  R Bültmann; M Trendelenburg; K Starke
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

9.  Evans blue blocks P2X-purinoceptors in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

10.  Blockade by 4,4'-diisothiocyanatostilbene-2,2'-disulphonate (DIDS) of P2X-purinoceptors in rat vas deferens.

Authors:  R Bültmann; K Starke
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

View more
  9 in total

1.  Development of a comprehensive set of P2 receptor pharmacological research compounds.

Authors:  R A Felix; S Martin; S Pinion; D J Crawford
Journal:  Purinergic Signal       Date:  2011-11-04       Impact factor: 3.765

2.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

3.  P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

Authors:  R Bültmann; B Pause; H Wittenburg; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

4.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Authors:  R Bültmann; H Wittenburg; B Pause; G Kurz; P Nickel; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

5.  8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Authors:  Joanna Lecka; Irina Gillerman; Michel Fausther; Mabrouka Salem; Mercedes N Munkonda; Jean-Philippe Brosseau; Christine Cadot; Mireia Martín-Satué; Pedro d'Orléans-Juste; Eric Rousseau; Donald Poirier; Beat Künzli; Bilha Fischer; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases).

Authors:  Younis Baqi; Stefanie Weyler; Jamshed Iqbal; Herbert Zimmermann; Christa E Müller
Journal:  Purinergic Signal       Date:  2008-06-05       Impact factor: 3.765

7.  Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds.

Authors:  Carsten Hoffmann; Petra Heine; Gabi Pradel; Yong-Chul Kim; Kenneth A Jacobson; Herbert Zimmermann
Journal:  Drug Dev Res       Date:  2001-01-24       Impact factor: 4.360

8.  Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1.

Authors:  Joanna Lecka; Michel Fausther; Beat Künzli; Jean Sévigny
Journal:  Mediators Inflamm       Date:  2014-08-11       Impact factor: 4.711

9.  Effects of exogenous nicotinamide adenine dinucleotide (NAD+) in the rat heart are mediated by P2 purine receptors.

Authors:  Vladislav S Kuzmin; Ksenia B Pustovit; Denis V Abramochkin
Journal:  J Biomed Sci       Date:  2016-06-27       Impact factor: 8.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.